Skip to main content
Quest Diagnostics

Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High Throughput Immunoassays Authorized for Emergency Use

Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High Throughput Immunoassays Authorized for Emergency Use

Authors: Prince HE, Givens TS, Lapé-Nixon M, Clarke NJ, Schwab DA, Batterman HJ, Jones RS, Meyer WA, Kapoor H, Rowland CM, Haji-Sheikhi F, Marlowe EM

Citation: J Clin Microbiol. 2020 Aug 18;JCM.01742-20. doi: 10.1128/JCM.01742-20. Online ahead of print.

Specialties: COVID-19, Dermatology, Infectious Disease

Download key summary

Related content

Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Test FAQ
SARS CoV 2 Antibody Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.